retatrutide phase 2 nejm weight loss 48 weeks (not yet approved in US but people using anyway) promises even potentially greater amongst the GLP1 drugs. https://www.nejm .org/doi/full/10.1056/NEJMoa2301972 Retatrutide - “Triple G” |
Description
Disclaimer: Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease
The company's marketplace replaces historically inefficient, expensive healthcare with a direct connection either virtually or in-person between patients and physicians
Hence, further studies are warranted to decipher the mechanisms
Body Composition and Lean Tissue Research
Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, such as tirzepatide, have transformed the management of type 2 diabetes and obesity through durable glycemic control, weight reduction, and cardiovascular protection
